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Abstract: Inﬂ  ammation, lipid peroxidation and chronic activation of the rennin – angiotensin 
system (RAS) are hallmarks of the development of atherosclerosis. Recent studies have sug-
gested the involvement of the pro-inﬂ  ammatory secretory phospholipase A2 (sPLA2)-IIA in 
atherogenesis. This enzyme is produced by different cell types through stimulation by pro-
inﬂ  ammatory cytokines. It is detectable in the intima and in media smooth muscle cells, not 
only in atherosclerotic lesions but also in the very early stages of atherogenesis. sPLA2-IIA 
can hydrolyse the phospholipid monolayers of low density lipoproteins (LDL). Such modiﬁ  ed 
LDL show increased afﬁ  nity to proteoglycans. The modiﬁ  ed particles have a greater tendency 
to aggregate and an enhanced ability to insert cholesterol into cells. This modiﬁ  cation may 
promote macrophage LDL uptake leading to the formation of foam cells. Furthermore, sPLA2-
IIA is not only a mediator for localized inﬂ  ammation but may be also used as an independent 
predictor of adverse outcomes in patients with stable coronary artery disease or acute coronary 
syndromes. An interaction between activated RAS and phospholipases has been indicated by 
observations showing that inhibitors of sPLA2 decrease angiotensin (Ang) II-induced macro-
phage lipid peroxidation. Meanwhile, various interactions between Ang II and oxLDL have been 
demonstrated suggesting a central role of sPLA2-IIA in these processes and offering a possible 
target for treatment. The role of sPLA2-IIA in the perpetuation of atherosclerosis appears to be 
the missing link between inﬂ  ammation, activated RAS and lipidperoxidation.
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Introduction
Atherosclerosis with its associated cardiovascular events, myocardial infarction (MI), 
sudden cardiac death or stroke, is one of the leading causes of death in the western 
countries (Ross 1999). Inﬂ  ammation and lipid peroxidation, as well as chronic activa-
tion of the renin-angiotensin system (RAS), are hallmarks of atherogenesis. Activated 
RAS, inﬂ  ammatory processes and lipid peroxidaton products contribute to the initia-
tion, progression and rupture of atherosclerotic plaques (Neaton et al 1992; Lowe 
et al 1998; Thomas et al 2002). Therefore reducing pro-inﬂ  ammatory mediators, and 
inhibiting the modulation of their releasing pathways, may be important both for the 
stability of atherosclerotic lesions and the perpetuation of atherosclerotic plaques 
(Taniguchi et al 2005).
In addition to this link, more direct interactions have been suggested between a 
chronically activated RAS, and elevated pro-inﬂ  ammatory cytokines and lipoproteins, 
which may also promote atherogenesis (Nickenig et al 2000). An increasing amount 
of evidence indicates that secretory phospholipase A2 (sPLA2) enzymes present in the 
vessel wall have localized effects that promote these processes (Kovanen et al 2000; Vascular Health and Risk Management 2008:4(3) 598
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Hurt-Camejo et al 2001; Niessen et al 2003; Tietge et al 
2005; Menschikowski et al 2006). Three members (group 
IIA, group V and group X) of the various sPLA2 isozymes 
have been detected in murine or human atherosclerotic 
lesions (Murakami et al 2004; Rosengreen et al 2004; Woo-
ton-Kee et al 2004); expression and localization of secretory 
phospholipase A2 group IIA (sPLA2-IIA) in human athero-
sclerotic tissue have been the best documented until now 
(Six et al 2000; Kudo et al 2002; Jaross et al 2002). In this 
context, recent investigations have suggested the involvement 
of sPLA2-IIA as part of a systemic and localized acute-phase-
reaction in the development of atherosclerosis, not only as 
a speciﬁ  c marker of inﬂ  ammation but probably as a central 
link between activated RAS and lipid peroxidation (Keidar 
et al 1997; Hayek et al 2000; Luchtefeld et al 2006; Divchev 
et al pers comm).
This study explains the importance of sPLA2-IIA as a key 
enzyme of inﬂ  ammation-based atherosclerotic development, 
and a prognostic marker of cardiovascular events, based on cur-
rent literature and the experimental ﬁ  ndings of our group.
What are phospholipases 
(in general sPLA2s) good for?
Phospholipases are enzymes that play a crucial role in the 
metabolism of phospholipids. Various groups and a remark-
able number of subgroups have been identiﬁ  ed, but speciﬁ  c 
functions for only some of these phospholipases have been 
established in humans. Their classiﬁ  cation is related to 
the site of action on the phospholipid molecules. In this 
context, phospholipases may act as acylhydrolases (PLAs 
and PLB), lysophospholipases or phosphodiesterases (PLC 
and PLD) (Six et al 2000; Kudo et al 2002). For example, 
phospholipases A2 (PLA2s) catalyze the sn-2 ester bonds of 
glycerophospholipids and, more importantly, appear to be 
the most inﬂ  uential subfamily in pro-inﬂ  ammatory processes 
and thereby in inﬂ  ammation-initiated diseases.
This subfamily can be characterized as a group of cal-
cium-dependent lipolytic enzymes with a preserved calcium-
binding loop and a His-Asp diad at the catalytic site. More 
then 13 groups and up to 20 different subgroups have been 
described so far (Six et al 2000; Kudo et al 2002; Jaross 
et al 2002). Nonsecretory PLA2s include the Ca2+-sensitive 
arachidonoyl-selective 85-kDa group IVα cytosolic PLA2 
(cPLA2α) (Leslie 1997; Bonventre 1999), paralogs of this 
enzyme (Pickard et al 1999), and several Ca2+-independent 
PLA2s (iPLA2s) (Balsinde et al 1997).
Many cell types can secrete sPLA2s, especially sPLA2-IIA 
such as mesangial cells (Pfeilschifter et al 1989; Schalkwijk 
et al 1991), vascular smooth muscle (Nakano et al 1990; 
Kurihara et al 1991), endothelial cells (Murakami et al 1993), 
platelets (Hayakawa et al 1988), mast cells (Foneth et al 
1994; Reddy et al 1996), neutrophils (Wright et al 1990), 
macrophages (Hidi et al 1993; Brabour et al 1993; Vial et al 
1995), and hepatic cells (Crowl et al 1991).
Several pro-inﬂ  ammatory stimuli may lead to secretion of 
diverse enzymes including phospholipases as part of a host 
defense mechanism. Such stimuli could be microbial patho-
gens as well as chemical irritants, allergens or physical stress 
factors. CPLA2α as well as the sPLA2s have been involved 
in various physiological and pathological functions such as 
release of pro-inﬂ  ammatory mediators, cell proliferation, 
ischemic injury, inﬂ  ammatory and allergic disease, lipid 
modiﬁ  cation, cancer, and antibacterial defense (Bonventre 
1999; Valentin et al 1999; Sapirstein et al 2000; Granata 
et al 2003). The presence of sPLA2-IIA activity in tears or 
seminal plasma, which may come into contact with bacterial 
pathogens, also suggests primary antibacterial properties of 
these enzymes. In this sense, sPLA2-IIA is able to destroy 
the membranes of Gram-positive bacteria. Interestingly, in 
Gram-negative bacteria sPLA2-IIA cannot directly attack the 
phospholipids of the intact cell membranes, but needs the 
cooperative action of neutrophils which produce bactericidal 
permeability-increasing protein (BPI) to support this function 
(Wright et al 1990; Laine et al 1999). Phospholipases could 
therefore act in the frame of combined inﬂ  ammation associ-
ated humoral and cellular responses.
SPLA2s do not exhibit acyl chain speciﬁ  city, whereas 
a preferential effect on arachidonic acid (AA)-containing 
membrane phospholipids, compared with those containing 
other fatty acids, could be demonstrated for cPLA2α. The 
cPLA2α, group IIA, and group V PLA2s are the primary 
PLA2s responsible for producing AA and its metabolites 
in endothelial, ﬁ  broblastic mast and macrophage cell lines 
(Balboa et al 1996; Reddy et al 1997; Pruzanski et al 1998). 
A profound cross-talk between cytosolic phospholipase A2 
(cPLA2) and sPLA2-IIA with regard to free radical release 
has been conﬁ  rmed by some investigations (Han et al 2003). 
Immunohistochemistry studies have further demonstrated the 
presence of group IIA, group V and group X secretory phos-
pholipase A2 in murine and human atherosclerotic lesions 
(Murakami et al 2004; Rosengren et al 2004; Wooton-Kee 
et al 2004; Webb 2005).
On the other hand, it could be shown that there are changes 
in serum cholesterol levels with decreased concentrations 
of high density (HDL) and low density lipoproteins (LDL) 
in patients suffering from generalized infectious diseases Vascular Health and Risk Management 2008:4(3) 599
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such as sepsis. Moreover, a frequent ﬁ  nding in patients with 
persisting infections, metastatic tumors or chronic inﬂ  am-
matory diseases is hypocholesterolemia (Green et al 1991; 
Vadas et al 1993). The serum concentration of sPLA2-IIA, 
especially the activity of the enzyme, is markedly increased 
in these diseases, acting as an acute-phase-reactant (de Beer 
et al 1997; Ivandic et al 1999; Menschikowski et al 2000).
In acute or chronic inﬂ  ammatory states, serum levels of 
pro-inﬂ  ammatory cytokines, such as interleukin (IL)-1β, IL-
6, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ are 
also increased and may induce sPLA2-IIA (Peilot et al 2000; 
Menschikowski et al 2000; Antonio et al 2002). These pro-
inﬂ  ammatory cytokines can also be released at an increased 
rate by the liver and locally by other cells especially within 
the atherosclerotic plaque. Such increased PLA2-activity 
in serum is thought to lead to a more efﬁ  cient clearance of 
lipoproteins mainly through the liver, thereby resulting in 
hypocholesterolemia (de Beer et al 1997; Ivandic et al 1999; 
Menschikowski et al 2000; Jaross et al 2002).
Therefore, early evidence suggested the existence of a 
central link between systemic as well as local inﬂ  ammatory 
processes and lipid metabolism, and that this link could be 
sPLA2-IIA.
The secretory phospholipase A2, 
group IIA role in atherogenesis
The key role played by sPLA2-IIA in the development of 
atherosclerosis, not merely as a mediator for localized inﬂ  am-
mation, has been indicated by a number of recent in-vitro 
and in-vivo studies as follows. The enzyme seems to play 
an important role as an integral modulator at several stages 
of atherogenesis.
In the arterial wall, sPLA2, especially sPLA2-IIA, may 
exert proatherogenic effects in multiple steps (Hurt-Camejo 
et al 2001). The isoenzyme sPLA2-IIA is located mainly 
in vascular smooth muscle cells of normal human arteries 
(Romano et al 1998; Sartipy et al 1998). In contrast, in ath-
erosclerotic plaques the enzyme is detectable within the lipid 
cores, in macrophage-rich regions and in the extracellular 
matrices of the affected intima. Furthermore, sPLA2-IIA has 
a close spatial relationship to collagen ﬁ  bres (Romano et al 
1998). As mentioned above, the expression of sPLA2-IIA in 
these cells is assumed to be up-regulated in vitro by several 
cytokines present in human atherosclerotic lesions, including 
IL-1β, TNF-α and IFN (Menschikowski et al 2000; Peilot 
et al 2000; Antonio et al 2002).
One of the ﬁ  rst important features in atherogenesis is 
the retention of LDL particles in the subendothelial space. 
The modiﬁ  cation of LDL mediated by sPLA2-IIA can change 
the structural organisation of the LDL particle leading to 
more pronounced lipid accumulation in the vessel wall. 
Such sPLA2-IIA modiﬁ  ed LDL are characterized through 
an increased afﬁ  nity for proteoglycans.
As a result of the hydrolytic activity, sPLA2-IIA releases 
free fatty acids and lyso-phosphatidylcholine(PC) (Yuan et al 
1995; Arbibe et al 1998; Fourcade et al 1998; Hurt-Camejo 
et al 2001; Hurt-Camejo et al 2001). This action may affect the 
functions and properties of vascular endothelial and smooth 
muscle cells, and of macrophages, at sites of LDL accumula-
tion (Sparrow et al 1988; Leitinger et al 1999). It should be 
noted that sPLA2-IIA prefers phosphatidic acid (PA) as sub-
strate over other phospholipids found in plasma membranes 
including phosphatidylserine (PS), phosphatidylcholine (PC) 
and phosphatidylethanolamine (PE). Sintko and colleagues 
reported the following order of substrate preference: PA  PE 
approximately PS  PC (Snitko et al 1997).
The ability of sPLA2-IIA to hydrolyze PC seems to be 
weak, but several conditions may amplify that function. 
sPLA2-IIA acts on oxidized (ox-)LDL more efﬁ  ciently by 
transforming LDL to a more atherogenic form. This action 
is based on the fact that oxidative modiﬁ  cation of phospho-
lipids increases their sPLA2-IIA susceptibility (Eckey et al 
1997). Furthermore, the closed spatial contact of sPLA2-IIA 
with matrix proteoglycans (in general decorin, biglycan and 
versican) may increase the hydrolytic activity of sPLA2-IIA 
toward PC in LDL (Sartipy et al 2000).
Moreover, sPLA2-IIA modified proteoglycan-bound 
lipoproteins show a greater tendency to aggregation and 
fusion. The result is a progressive deposition of lipids within 
the extracellular matrices of the arterial intima (Hakala et al 
2001). In addition to enhancing the retention of LDL particles 
in the vessel wall, there is also evidence that sPLA2 modiﬁ  ca-
tion may promote macrophage LDL uptake, leading to foam 
cell formation (Heinecke et al 1991; Aviram et al 1992).
It should be noted that other sPLA isoenzymes detectable 
in circulation and human atherosclerotic lesions, especially 
of group V and group X, have more potent actions on 
lipoproteins compared with sPLA2-IIA (Bezzine et al 2000; 
Hanasaki et al 2002; Gesquiere et al 2002). Obviously, 
the sole potency of sPLA2-IIA in hydrolyzing the primary 
substrates phosphatidylethanolamine and phosphatidylserine 
may not be the only important feature in atherosclerotic 
plaque perpetuation, especially in transforming LDL into 
more atherogenic forms. Interestingly, sPLA2-V has a pref-
erential action in hydrolysis of HDL compared with LDL, 
as reviewed by Murakami and Kudo (2003). Similar to Vascular Health and Risk Management 2008:4(3) 600
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sPLA2-V, sPLA2-X deﬁ  nitely shows more pronounced PC-
hydrolysing activity. On the other hand, sPLA2-X modiﬁ  ed 
LDL particles have a lower tendency to aggregate (Hanasaki 
et al 2002; Murakami et al 2003). Nevertheless, we can sup-
pose that sPLA2 isoenzymes may act synergistically under 
certain conditions (Shoda et al 1999).
Together, HDL and apolipoprotein A-I(apoA-I) are posi-
tive prognostic factors in preventing perpetuation of arterio-
sclerotic plaque formation; there is increasing evidence that 
sPLA2-IIA may transform these particles to pro-atherogenic 
and pro-inﬂ  ammatory reactants. As shown by de Beer and 
colleagues, sPLA2-IIA dependent hydrolysis of HDL results 
in a more efﬁ  cient scavenger receptor class B type I choles-
teryl ester uptake, leading to an accelerated HDL catabolism 
in the kidney during inﬂ  ammatory states (deBeer et al 2000). 
Moreover, HDL- and ApoA-I-catabolism as well as HDL-
cholesteryl ester tissue uptake were signiﬁ  cantly enhanced 
under conditions of sPLA2-IIA overexpression even in the 
absence of inﬂ  ammatory preconditions (Tietge et al 2000).
The above mentioned effects promoted by sPLA2-IIA 
– in general the release of AA – are primarily based on 
increased enzyme activity. However, the noteworthy non-
enzymatic properties of sPLA2-IIA can also contribute to 
atherogenesis. In this way, catalytic inactive sPLA2-IIA was 
shown to promote COX-2 expression in mast cells (Tada 
et al 1998). Further effects may be mediated by the sPLA2 
M-type receptor on smooth muscle cells independent of 
enzyme activity (Silliman et al 2002) and by activating 
signaling pathways such as ERK (Han et al 2003) MAP 
kinases or protein kinase C (Hernandez et al 1998). Further 
research is needed to make clear whether these effects are 
present in atherosclerotic lesions, and how far they may 
contribute to atherogenesis.
sPLA2-IIA as a prognostic 
marker in coronary artery disease
In a similar way to chronic inﬂ  ammatory diseases, plasma 
levels of sPLA2-IIA were shown to be elevated in patients 
with coronary artery disease (CAD) and to predict coronary 
events in asymptomatic patients or patients with stable angina 
(Kugiyama et al 1999). Moreover, increased plasma levels 
of sPLA2 in stable patients undergoing percutaneous coro-
nary angioplasty (PCI) also provide independent prognostic 
information over other classic cardiovascular risk factors and 
clinical covariables (Liu et al 2003). The prognostic value 
of sPLA2-IIA in patients with acute coronary syndromes 
(ACS) was ﬁ  rst described in a study of patients with unstable 
angina by Kugiyama and colleagues (2000). Increased plasma 
levels of sPLA2-IIA predicted recurrent coronary events, 
mainly revascularization procedures, independently of other 
established risk factors (Kugiyama et al 2000). Mallat and 
colleagues (2007) also evaluated the prognostic importance 
of plasma sPLA2-IIA levels and enzyme activity across 
the entire spectrum of ACS by recruiting patients from the 
Global Registry of Acute Coronary Events (GRACE). In this 
impressive study, they showed that plasma sPLA2 activity, in 
contrast to CRP or IL-18, was a major independent predictor 
of death and new or recurrent myocardial infarction (MI) in 
patients with ACS. Interestingly, total sPLA2-activity had a 
better prognostic value than the sPLA2-IIA antigen level.
However the study’s most important ﬁ  nding was the fact 
that a single determination of sPLA2-activity, obtained during 
the two days after the onset of ischemic symptoms, provides 
powerful prognostic information in patients with ACS. The 
association between sPLA2 activity and the risk of subsequent 
death or MI was independent of the other known predictors 
of major adverse outcomes in patients with ACS, including 
the presence or absence of a history of MI or signs of heart 
failure at admission (Mallat et al 2005).
Additional evidence to conﬁ  rm the importance of cata-
lytic activity, as well as an elevated sPLA2-IIA antigen level, 
was gathered by Korotaeva and colleagues (2005). They 
demonstrated that sPLA2-IIA is involved in the development 
of restenosis after PTCA in human coronary arteries and in 
the generation of atherogenic LDL (Korotaeva et al 2005).
Interestingly, sPLA2-IIA also seems to play an impor-
tant role in predicting risk for coronary artery disease and 
adverse coronary events in healthy subjects, especially when 
combined with other pro-inﬂ  ammatory risk factors like CRP 
(Boekholdt et al 2005; Mallat et al 2007).
Thus sPLA2-IIA can be shown to be not only a mediator 
for localized inﬂ  ammation but also a powerful independent 
predictor of adverse outcomes in patients with stable CAD, 
or in acute coronary syndromes.
Angiotensin, LDL-peroxidation, 
and atherogenesis
Early evidence of a potential role for angiotensin (Ang) II in 
LDL oxidation was gathered by Keidar (1998) who reported 
that the LDL of hypertensive patients was more responsive 
to oxidative modiﬁ  cation than the LDL of normotensive 
subjects. Meanwhile, various interactions between Ang II 
and oxLDL have been demonstrated especially by the Keidar 
group. For example, Ang-II injection into apolipoprotein E-
deﬁ  cient (E0) mice led to increased cellular oxLDL uptake 
by their peritoneal macrophages (MPMs) via proteoglycan Vascular Health and Risk Management 2008:4(3) 601
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macrophage stimulation pathway, a process mediated by Il-6 
(Keidar et al 1995, 2001). In human coronary endothelial 
cells, Ang-II enhanced the oxLDL-uptake by up-regulating 
the lectin-like receptor for oxLDL (LOX-1). This effect 
could be blocked by the angiotensin receptor blockers 
(ARBs) Losartan and Candesartan (Mehta et al 2001, 2002). 
Ang-II increased the cellular lipid peroxidation of MPMs by 
50%–100%. Moreover, Ang-II enhanced scavenger receptor 
afﬁ  nity to oxLDL on macrophages (Keidar 1998).
The effects of Ang-II are predominantly mediated via 
activation of the AT1-receptor which is coupled through 
guanine nucleotide binding proteins (G-proteins), adenylate 
cyclase and cyclic adenosine monophosphate (cAMP) as 
second messenger, as well as phospholipases A2, C and D and 
their products, arachidonic acid (AA), inositol triphosphate 
(IP3), or diacylglycerol (DG).
The mechanism of Ang-II-mediated cellular lipid 
peroxidation involved Ang-II binding to its cellular receptor 
underlined by the fact that preincubation of the cells with the 
Ang-II antagonist, saralasin, completely inhibited this effect. 
Inhibitors of phospholipase A2, C and D also substantially 
reduced Ang-II-induced macrophage lipid peroxidation 
(Keidar et al 1995).
Interestingly, AT1-receptor blockade with Losartan inhib-
ited LDL oxidation and macrophage cholesterol biosynthesis 
(Keidar et al 1999), and attenuated atherosclerosis in E0 mice 
(Keidar et al 1997). In a trial by Hayek and colleagues (2000), 
losartan therapy for a period of 4 weeks did not signiﬁ  cantly 
affect the degradation of native LDL monocyte-derived mac-
rophages (HMDM) derived from patients. However, Losartan 
therapy signiﬁ  cantly reduced HMDM uptake of oxLDL as 
shown by a 78% reduction in oxLDL cell-association and 
a 21% reduction in oxLDL degradation (Hayek et al 2000), 
a ﬁ  nding which has been also conﬁ  rmed for other ARBs 
(Metha et al 2001, 2002).
All these ﬁ  ndings suggested an integral link between 
angiotensin II (Ang-II) and its receptor mediated effects, and 
activation of pro-inﬂ  ammatory and pro-atherogenic pathways 
which could further promote lipid peroxidation.
sPLA2-IIA, the possible link between 
activated RAS, inﬂ  ammation, 
and lipidperoxidation: a target 
for treatment?
As mentioned above, angiotensin II type 1 (AT1)-receptor 
blockade may reduce LDL-modiﬁ  cation and atherosclerotic 
plaque formation in animal models of atherosclerosis. 
Furthermore, Cassis and colleagues (2007) demonstrated that 
AT1-mediated atherogenesis is dependent on AT1 expression 
in the vessel wall, and that the presence of this receptor in 
resident tissues is required to initiate AngII-induced athero-
sclerosis. Because of increasing evidence for involvement of 
sPLA2-IIA in modifying LDL, our group assessed whether 
ANG II, via its AT1-receptor, enhances sPLA2-IIA-dependent 
lipid peroxidation in vitro and in patients with CAD. There-
fore, rat aortic smooth muscle cells were stimulated with ANG 
II. This stimulation resulted in enhanced sPLA2-IIA protein 
expression and sPLA2-IIA activity. LDL-peroxidation was 
consequently enhanced by ANG II. Interestingly, all these 
effects could be reduced by AT1-receptor blockade with 
losartan. Furthermore, ANG II-induced sPLA2 activity and 
LDL-peroxidation were prevented by the sPLA2-IIA activity 
inhibitor LY311727 (Luchtefeld et al 2006).
These findings suggested that sPLA2-IIA activa-
tion could be the supposed link between activated RAS 
and lipidperoxidation, and that ANG II may elicit pro-
atherosclerotic effects via sPLA2-IIA-dependent LDL-
modiﬁ  cation.
In order to evaluate potential clinical implications of these 
ﬁ  ndings, a small number of patients with angiographically 
documented CAD were treated with the AT1-receptor blocker 
irbesartan (300 mg/d) for 12 weeks. Blood samples were 
obtained from patients pre- and post-treatment and from 
healthy volunteers. SPLA2-IIA serum level and activity, 
circulating antibodies against oxidized LDL (oxLDL) and 
oxLDL, were determined in patients and found to be signiﬁ  -
cantly increased compared to healthy volunteers. Irbesartan 
therapy reduced these markers of inﬂ  ammation, whereas total 
cholesterol, HDL- and LDL-fractions remained unchanged 
(Luchtefeld et al 2006).
Based on these ﬁ  ndings we investigated further the 
potential effect of a combined treatment with pravastatin and 
irbesartan on oxLDL and sPLA2-IIA in a group of patients 
with CAD. We postulated that the addition of an AT1-receptor 
antagonist to the standard secondary prevention therapy with 
a statin might exert additional effects on LDL oxidation and 
sPLA2-IIA. We demonstrated that both treatment regimens 
comparably inﬂ  uenced LDL-cholesterol levels. However, 
sPLA2 activity was reduced only in patients treated with the 
adjunction of pravastatin and irbesartan. Consequently, only 
the combined treatment resulted in a signiﬁ  cant reduction of 
ox-LDL levels independent of changes in LDL cholesterol 
(Divchev et al pers comm).
All these ﬁ  ndings suggest a possible role for AT1-receptor 
blockade in reducing LDL-peroxidation. Whether these Vascular Health and Risk Management 2008:4(3) 602
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effects can reduce the perpetuation of atherosclerosis and 
especially adverse cardiovascular events in patient with CAD 
remains to be elucidated in further studies.
Conclusion
In conclusion, secretory phospholipases A2 (in general 
sPLA2-IIA) were shown to play an important role in athero-
genesis. Furthermore, the activity of sPLA2-IIA is a powerful 
independent predictor of adverse events in stable patients 
with CAD and in ACS. Focusing on recent data, expression 
and activation of sPLA2-IIA in atherosclerotic lesions seemed 
to be one of the links between activated RAS, inﬂ  ammation 
and the processes of lipid accumulation and lipid peroxida-
tion in the vessel wall as main features of atherosclerosis. 
Therefore, direct inhibition of sPLA2-IIA through speciﬁ  c 
antagonists, or indirectly through AT1-receptor blockade, 
might be a new therapeutic option used to intervene in this 
detrimental process of plaque development. The conﬁ  rma-
tion of these therapeutic effects and their relevance in human 
atherosclerosis remain the foremost challenges.
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